SCHEMBL1678043

SCHEMBL1678043

CC1(NC(=O)O)N=c2ccc(C(=O)c3ccccc3)cc2=N1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 3/20 0.43
ATM Q13315 1/20 0.43
TDP1 Q9NUW8 1/20 0.43
RAB9A P51151 5/20 0.42
ALDH1A1 P00352 4/20 0.42
HPGD P15428 3/20 0.42
SMN1; SMN2 Q16637 2/20 0.42
POLB P06746 1/20 0.42
NPC1 O15118 4/20 0.40
SRD5A2 P31213 1/20 0.40
MAPK13 O15264 1/20 0.39
MAPK12 P53778 1/20 0.39
MAPK11 Q15759 1/20 0.39
MAPK14 Q16539 1/20 0.39
CNR2 P34972 1/20 0.39
MEN1 O00255 1/20 0.39
KMT2A Q03164 1/20 0.39
GLA P06280 1/20 0.38
CYP1A2 P05177 1/20 0.38
CYP2D6 P10635 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL966475 0.81 SMN1; SMN2 (0.34) L3MBTL1RAB9AALDH1A1HPGDSMN1; SMN2
SCHEMBL11393102 0.76
Phosphoric Acid SCHEMBL11599912 0.75 SMN1; SMN2 (0.33) TDP1RAB9AALDH1A1HPGDSMN1; SMN2
SCHEMBL10492822 0.66 ATM (0.52) L3MBTL1ATMTDP1RAB9AALDH1A1
SCHEMBL166495 0.66 SMN1; SMN2 (0.71) L3MBTL1ATMTDP1RAB9AALDH1A1
SCHEMBL10007010 0.66 SMN1; SMN2 (0.71) L3MBTL1ATMTDP1RAB9AALDH1A1
SCHEMBL9066312 0.66 ALDH1A1 (0.93) L3MBTL1ATMTDP1RAB9AALDH1A1
SCHEMBL314267 0.66 ALDH1A1 (0.93) L3MBTL1ATMTDP1RAB9AALDH1A1
SCHEMBL4609604 0.65 POLB (0.57) L3MBTL1ATMTDP1ALDH1A1HPGD
SCHEMBL259065 0.64 ALDH1A1 (0.80) L3MBTL1ATMTDP1RAB9AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2310009-B1 PARENTERAL AND ORAL FORMULATIONS OF BENZIMIDAZOLES UNIV HOUSTON (US) 2017-12-20 EP claimed
US-9259390-B2 Parenteral and oral formulations of benzimidazoles THE UNIVERSITY OF HOUSTON SYSTEM (US) 2016-02-16 US claimed
US-9259391-B2 Parenteral and oral formulations of benzimidazoles THE UNIVERSITY OF HOUSTON SYSTEM (US) 2016-02-16 US claimed
EP-2310009-A2 PARENTERAL AND ORAL FORMULATIONS OF BENZIMIDAZOLES UNIVERSITY OF HOUSTON (US) 2011-04-20 EP claimed
US-20100310611-A1 Parenteral and oral formulations of benzimidazoles CHOW DIANA SHU-LIAN 2010-12-09 US claimed
WO-2010011289-A2 PARENTERAL AND ORAL FORMULATIONS OF BENZIMIDAZOLES UNIVERSITY OF HOUSTON (US) 2010-01-28 WO claimed
US-20090048322-A1 Parenteral and oral formulations of benzimidazoles UNIVERSITY OF HOUSTON SYSTEM, THE 2009-02-19 US claimed
US-20080293796-A1 Parenteral and oral formulations of benzimidazoles UNIVERSITY OF HOUSTON SYSTEM, THE 2008-11-27 US claimed
US-7423015-B1 Antihelminthic drugs as a treatment for hyperproliferative diseases BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) 2008-09-09 US claimed
US-7419996-B2 Parenteral and oral formulations of benzimidazoles THE UNIVERSITY OF HOUSTON (US) 2008-09-02 US claimed
WO-2005018623-A2 PARENTERAL AND ORAL FORMULATIONS OF BENZIMIDAZOLES THE UNIVERSITY OF HOUSTON (US) 2005-03-03 WO claimed
US-20050038096-A1 Parenteral and oral formulations of benzimidazoles THE UNIVERSITY OF HOUSTON 2005-02-17 US claimed
EP-1425012-A1 ANTIHELMINTHIC DRUGS AS A TREATMENT FOR HYPERPROLIFERATIVE DISEASES Board of Regents, The University of Texas System (US) 2004-06-09 EP claimed
WO-2002067932-A1 ANTIHELMINTHIC DRUGS AS A TREATMENT FOR HYPERPROLIFERATIVE DISEASES BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) 2002-09-06 WO claimed
US-20250241898-A1 Topical Benzimidazole Formulations and Methods for Use in Treating Inflammatory Dermatoses JJR&D, LLC 2025-07-31 US disclosed
EP-4543441-A2 TOPICAL BENZIMIDAZOLE FORMULATIONS AND METHODS FOR USE IN TREATING INFLAMMATORY DERMATOSES JJR&D, LLC (US) 2025-04-30 EP disclosed
US-20240423959-A1 TOPICAL BENZIMIDAZOLE FORMULATIONS AND METHODS FOR USE IN TREATING INFLAMMATORY DERMATOSES JJR&D, LLC 2024-12-26 US disclosed
WO-2002067932-A1 ANTIHELMINTHIC DRUGS AS A TREATMENT FOR HYPERPROLIFERATIVE DISEASES BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) 2002-09-06 WO disclosed
US-5985795-A CONTAINS INORGANIC METAL ANTIMICROBIAL AGENT, THIAZOLE ANTIMICROBIAL AGENT, HALOALKYLTHIO ANTIMICROBIAL AGENT, IMIDAZOLE ANTIMICROBIAL AGENT, AND UREA ANTIMICROBIAL AGENT Suganuma, Akio (JP) 1999-11-16 US disclosed
EP-0834253-A2 Antimicrobial composition Suganuma, Akio (JP) 1998-04-08 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100310611-A1 Parenteral and oral formulations of benzimidazoles SBDS, HBZ, PAICS L3MBTL1 1368/4885ATM 3306/4885TDP1 4839/4885
US-20050038096-A1 Parenteral and oral formulations of benzimidazoles PAICS, SBDS, PBRM1 L3MBTL1 856/4885ATM 3889/4885TDP1 4371/4885
US-20080293796-A1 Parenteral and oral formulations of benzimidazoles SBDS, MRPL38, CYP3A7 L3MBTL1 1964/4885ATM 3464/4885TDP1 4530/4885
US-20090048322-A1 Parenteral and oral formulations of benzimidazoles SBDS, HBZ, PAICS L3MBTL1 1368/4885ATM 3306/4885TDP1 4839/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.